Over the past few years, PLK1 inhibition has emerged as an attractive option for melanoma treatment in combination with MEK inhibition (Posch et al, 2015; Kohtamaki et al, 2022; Yu et al, 2022), NOTCH inhibition (Su et al, 2021), or in the case of resistance to directed therapies (BRAF and MEK inhibition [Sanchez et al, 2019]). This evidence concerns the gene MAP2K7 and melanoma.